Senior Director, HCP Marketing
Description :
The Senior Director, HCP Marketing will lead the strategic development and tactical execution of the launch plan that drives awareness and adoption of Viaskin ® peanut patch among Allergists and other relevant Healthcare Providers (HCPs). This role serves as the strategic owner of HCP messaging across personal and non-personal channels.
Location : Warren, New Jersey - 3 days on site & 2 days remote
Salary Range : 140-165K
Key Responsibilities :
HCP Marketing Strategy & Leadership
Develop HCP marketing strategies that reflect a deep understanding of customer journeys in the pediatric peanut allergy market.
Implement HCP marketing programs across personal and non-personal efforts aimed at Allergists (primary focus) and other relevant HCPs
Direct the translation of complex clinical data into compelling HCP messaging to define the HCP messaging framework
Ensure all HCP tactics are insight-driven, measurable, and communicate the value proposition of VIASKIN Peanut to HCPs
Hire and manage at least one direct report
Salesforce Strategy & Personal Promotion
Lead development of all field resources to support meaningful customer engagements (e.g., detail aids, digital tools, peer-to-peer programs, congress materials)
Partner closely with Sales Training and Field Leadership to develop and ensure a comprehensive, on-going training program will produce a well-educated, unparalleled winning sales team
Regularly collect and incorporate field feedback and performance insights to continuously optimize materials and messaging for the greatest results
Non-Personal Promotion (NPP)
Direct omni-channel execution with non-personal promotion to Allergists and other relevant HCPs
Lead development of all non-personal programs across multiple channels to deliver impactful content that drives HCP adoption of VIASKIN Peanut
Develop content customized to each channel that reinforces field promotion for VIASKIN while reaching a much larger audience
Cross-Functional Collaboration
Build strong relationships across the launch team including market research, sales operations, market access, and field leadership.
Manage vendor partnerships to execute at launch pace
Own HCP marketing budgets, timelines, and prioritization
Qualifications :
Skills :
A bachelor’s degree is required, with an advanced degree in business, life sciences, or related field preferred.
10+ years of experience leading HCP marketing in specialty pharma or biotech, launch experience highly preferred
Strong understanding of the food allergy landscape preferred
Proven record of success in developing customer-centric marketing strategies and optimizing them through omnichannel marketing
Proven record of success in developing compelling field aids for personal promotion
Strong understanding of promotional compliance, MLR processes, and regulatory requirements
Strategic thinker with strong executional discipline and cross-functional influence
Behavioral skills :
Curiosity: Keep on exploring uncharted territories. Always ask “why?” and more importantly “why not?”,
Courage: Take smart risks, mentor each other to always do better & be accountable for our choices, our opinions, and our actions,
Collaboration: Teamwork and spirit. Support each other and be equally involved in the achievement of our common goals,
Credibility: Be transparent, follow through and build trust. Educate ourselves about our unique technology.
- Locations
- US - Warren, NJ
- Remote status
- Hybrid
About DBV Technologies
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.
Already working at DBV Technologies?
Let’s recruit together and find your next colleague.